Follow
Willy Hugo, PhD
Willy Hugo, PhD
UCLA School of Medicine
Verified email at mednet.ucla.edu
Title
Cited by
Cited by
Year
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
W Hugo, JM Zaretsky, L Sun, C Song, BH Moreno, S Hu-Lieskovan, ...
Cell 165 (1), 35-44, 2016
29712016
Mutations associated with acquired resistance to PD-1 blockade in melanoma
JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ...
New England Journal of Medicine 375 (9), 819-829, 2016
29282016
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ...
Cell Reports 19 (6), 1189-1201, 2017
16132017
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
Cancer discovery 7 (2), 188-201, 2017
11582017
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ...
Nature medicine 25 (3), 477, 2019
10842019
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ...
Cancer discovery 4 (1), 80-93, 2014
1044*2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ...
Nature communications 5, 5712, 2014
6322014
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
W Hugo, H Shi, L Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ...
Cell 162 (6), 1271-1285, 2015
6052015
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction
G Moriceau, W Hugo, A Hong, H Shi, X Kong, CY Clarissa, RC Koya, ...
Cancer cell 27 (2), 240-256, 2015
3712015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
DB Johnson, AM Menzies, L Zimmer, Z Eroglu, F Ye, S Zhao, H Rizos, ...
European Journal of Cancer 51 (18), 2792-2799, 2015
3342015
Regional Glutamine Deficiency in Tumours Promotes De-differentiation through Inhibition of Histone Demethylation
M Pan, MA Reid, XH Lowman, RP Kulkarni, TQ Tran, X Liu, Y Yang, ...
Nature cell biology 18 (10), 1090, 2016
3272016
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
TJ Parmenter, M Kleinschmidt, KM Kinross, ST Bond, J Li, MR Kaadige, ...
Cancer discovery 4 (4), 423-433, 2014
2892014
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017; 7: 188–201. doi: 10.1158/2159-8290
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
CD-16-1223.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
250
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition
H Shi, A Hong, X Kong, RC Koya, C Song, G Moriceau, W Hugo, ...
Cancer discovery 4 (1), 69-79, 2014
1822014
Recurrent tumor cell-intrinsic and-extrinsic alterations during MAPKi-induced melanoma regression and early adaptation
C Song, M Piva, L Sun, A Hong, G Moriceau, X Kong, H Zhang, S Lomeli, ...
Cancer Discovery, CD-17-0401, 2017
1542017
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
A Lee, L Sun, A Mochizuki, J Reynoso, J Orpilla, F Chow, J Kienzler, ...
1062021
Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
A Hong, G Moriceau, L Sun, S Lomeli, M Piva, R Damoiseaux, SL Holmen, ...
Cancer Discovery 8 (1), 74-93, 2018
1022018
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
E Pérez-Guijarro, HH Yang, RE Araya, R El Meskini, HT Michael, ...
Nature Medicine 26 (5), 781-791, 2020
892020
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
AA Marusiak, ZC Edwards, W Hugo, EW Trotter, MR Girotti, ...
Nature communications 5, 2014
842014
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
B Titz, A Lomova, A Le, W Hugo, X Kong, J Ten Hoeve, M Friedman, H Shi, ...
Cell Discovery 2, 16028, 2016
682016
The system can't perform the operation now. Try again later.
Articles 1–20